Uscom
Improving Life Expectancy Through Non-Invasive Monitors

Patient monitoring is an integral element of any medical therapy; without the correct medical monitoring equipment, it could result in fatality. Recent technological advancements have aided the healthcare sector with both invasive and non-invasive monitoring equipment. Invasive hemodynamic monitoring techniques might result in hematoma development, bleeding, or infection. To decrease the danger factor in monitoring, companies began creating non-invasive technologies. However, Medical professionals are wary of using non-invasive technology because they fear it will not offer sufficient information about the heart or lungs. Proving this wrong is Uscom, a company that develops non-invasive practice-changing suites of devices in the field of cardiac, vascular, and pulmonary monitoring.

Since its inception in 2000, through translational cardiovascular research, the company produced the USCOM 1A, a sophisticated hemodynamic monitor device that was released to the market in 2006 and is now the company’s cornerstone product. The device uses advanced Doppler hemodynamic to monitor cardiac blood flow. Owing to stroke volume (SV) monitoring, the way fluid, inotropes, and vaso-actives are controlled, as well as how sepsis, heart failure, and hypertension are treated, is changing. USCOM 1A is very reliable in medical scenarios such as in sinus rhythm, atrial fibrillation, vasopressors, on and off ventilation, or experiencing autonomic regulatory changes. Appropriate use of the device reduces the mortality rate in septic shock patients. The device is outstandingly optimum in saving lives in neonatal, pediatric, critical care, emergency, perioperative, oncological, maternal, and perinatal populations.

Aside from the USCOM 1A, the firm also offers the BP+ and SpiroSonic devices, which do blood pressure (BP) monitoring and pulmonary function testing, respectively.

The Uscom BP+ is the rising standard of treatment in hypertension, heart failure, and vascular health, replacing older and more widely used sub-systolic BP monitors. The BP+ is a supra-systolic oscillometric central monitor that keeps track of BP and BP waveforms in the heart and arm, data that was previously only available through invasive cardiac catheterization. Central BP is a better indication of BP that affects the inner organs than peripheral BP. The treatment of central BP differs from that of brachial BP. The device is easy to use and does not require much training. It may be used in hypertension, heart failure, critical care, general practice, and home care.

Uscom’s SpiroSonic digital ultrasonic spirometers are digital pulmonary function testing instruments that use multi-path ultrasound technology to provide high-quality results. To enable remote telemonitoring of pulmonary illness, SpiroSonic devices can be combined with mobile phone applications and proprietary software platforms with a wireless interface. The SpiroSonic Suite includes user-friendly digital respiratory devices that provide cost-efficient, high-quality spirometry.

Each product is the culmination of years of study, technical advancement, and invention based on ultrasonic flow measurements and ultrasonic spirometry. Uscom has an aggressive global growth strategy, which has resulted in the acquisition of practice-changing and complimentary non-invasive cardiovascular and pulmonary technologies. The organization has a strong product pipeline projecting well into the next ten years. Uscom is aligned with world leaders in multiple clinical disciplines and benefits from their scientific guidance and close engagement with its team. The company is looking to deliver its non-invasive practice-changing devices worldwide with assistance from its partners.Uscom’s value is founded on clinical benefit, and the company takes pleasure in developing products that contribute to better treatment.